United States · Markets & Finance · The Motley Fool

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Published by The Motley Fool · United States 9 h ago

Evidence from two large-scale studies (NHS-Galleri in England and a 35,878-enrollment study in the U.S., (PATHFINDER 2) shows that Galleri performs better on the 12 deadly cancers…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Seeking Alpha

Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline

NYT Business

E.E.O.C. Sues Harvard for Data on Diversity in Hiring Practices

CNBC

Trump's meeting with tech leaders leaves AI safety more unsettled than ever

CoinDesk

Open USD takes on Tether, Circle with a different stablecoin model that's 'building money'

Quartz

The 'Gen Z stare' is telling us something important about today's economy

TechCrunch